Beyond Snapshots: How Continuous Data Is Advancing Cardiac Research and Treatment

A patient with chronic heart failure comes in for a scheduled follow-up every three months. At the visit, the care team reviews weight, symptoms, medications, device data if available, and a limited set of cardiac measurements. The patient appears stable in the clinic. But between visits, their physiology may be telling a more complicated story.

Maybe their rhythm burden is increasing at night. Maybe their heart rate variability is changing after a medication adjustment. Maybe subtle hemodynamic shifts are building for days before symptoms appear. In a traditional episodic model, those signals can be missed because the care team is forced to make decisions from snapshots: a few data points representing thousands of hours of cardiac activity.

The stakes are real. A 2025 propensity-matched analysis in JMIR found that medical ward patients who received intermittent vital sign monitoring had nearly three times greater odds of ICU admission or in-hospital mortality compared with patients receiving continuous monitoring, with an odds ratio of 2.79. Another 2026 study notes that, in UK data, 23% of in-hospital deaths tied to severe adverse events resulted from failures to recognize or respond to patient deterioration.

Cardiac disease does not progress in snapshots. It evolves continuously, through subtle waveform shifts, gradual hemodynamic trends, and treatment response patterns that unfold over hours and days. When research and clinical decisions are built on episodic data, the gaps between measurements become blind spots. Continuous data capture helps close those gaps, enabling more precise research, earlier detection, and more individualized treatment strategies.

What Gets Lost Between Measurements

Episodic data has long shaped the way cardiac care is delivered and studied. It is familiar, structured, and easier to review than streams of high-resolution physiologic information. But it also limits what clinicians and researchers can see.

Treatment response is one example. A patient started on a new antiarrhythmic may look stable at a follow-up visit, but that visit may not reveal how their rhythm stability changed during the first several days of therapy. It may not show whether their heart rate variability improved, whether episodes clustered at certain times, or whether the patient’s response changed as the medication reached steady state.

Without continuous cardiac data, dose adjustments, medication switches, and intervention timing may be guided by incomplete evidence. The patient’s response is reduced to what was captured at the moment of measurement.

Disease progression can also hide in the intervals. Heart failure, atrial fibrillation, and post-MI recovery rarely worsen in clean, discrete steps. They often evolve through small changes: a gradual rise in resting heart rate, shifting blood pressure variability, changes in ST morphology, or increasing rhythm instability. These patterns may be difficult to detect through periodic vitals or scheduled assessments. They become more visible when clinicians and researchers can evaluate continuous waveform data over time.

Research built on episodic data inherits the same blind spots. When clinical studies rely on point-in-time measures, treatment effect can appear different depending on when the measurement is taken. A therapy may look effective at one scheduled interval while missing variability, delayed response, or transient deterioration between visits.

This matters for clinical trials, quality improvement, and outcomes research. The FDA’s guidance on digital health technologies for remote data acquisition provides recommendations for using hardware and software to collect data remotely from participants in clinical investigations. The guidance also notes that digital health technologies may improve trial efficiency and make participation more convenient. For cardiac research, this supports a broader shift toward data collection models that capture more of the patient’s physiologic experience beyond scheduled visits.

What Continuous Cardiac Data Makes Possible

Continuous, high-resolution cardiac data changes the level of detail available across an organization. Its value compounds as different teams use and reuse this data in their work. to manage a patient at the bedside tonight, or to analyze outcomes across a population next year.

At the bedside, continuous monitoring transforms daily care delivery from a reactive workflow into a proactive one. Instead of relying on scheduled assessments, care teams can evaluate subtle physiologic trends across the full arc of a patient’s immediate treatment response.

• Clinicians can identify subtherapeutic responses earlier, catch medication changes that require adjustments before symptoms manifest, and refine protocols based on actual, live physiologic trajectories.
• Signals such as trending bradycardia, evolving rhythm instability, and changing heart rate variability frequently appear hours before an acute event becomes clinically obvious. A 2024 Critical Care roadmap notes that variability derived from heart rate, respiratory rate, and blood pressure waveforms contains vital diagnostic and prognostic signatures that can signal reduced physiologic reserve.
• For cardiac telemetry monitoring, preserving the continuous physiologic is about turning raw noise into actionable intelligence, allowing bedside teams to act with greater confidence and fewer false alarms.

At scale, capturing this high-resolution data can also create a robust strategic asset for academic medical centers and health systems. When paired with the right clinical analytics platform and data governance, continuous data supports organizational priorities that episodic records simply cannot touch.

• Retrospective data allows informatics leaders to develop predictive models, design stronger quality improvement programs, and establish internal clinical baselines based on vast, high-fidelity datasets.
• Because researchers are often looking for broad patterns, access to thousands of hours of continuous waveform data helps teams map out complex disease progression and capture treatment response variability across diverse patient populations.
• Transitioning from locked bedside monitors to a centralized, searchable data ecosystem gives health systems the foundation needed to build, test, and validate machine learning models and clinical decision support tools over time.

How Sickbay Enables Continuous Cardiac Data for Research and Clinical Precision

Hospitals that have successfully closed these visibility gaps understand the value of patient monitoring infrastructure in supporting both immediate clinical awareness and long-term research value. Sickbay’s vendor-neutral, FDA-cleared solution connects continuous, high-resolution physiologic data to clinical and research workflows.

Sickbay understands the value of complete data, available on-demand. For example, when it comes to cardiac emergencies, seconds matter. Sickbay delivers the capability to track and record second-by-second physiological data, effectively eliminating historical gaps across different care environments.

Consider the transition from the Emergency Room to inpatient units. Historically, when a patient suffered a transient cardiac event or a brief run of V-Tach in the ER, their data was permanently lost the moment they were disconnected from the ER monitor and transferred. The incoming cardiology team had to take the ER staff’s word for it, relying on manual charting and point-in-time summaries.

With Sickbay, those workflows are connected. “Now that Sickbay captures that data in the ER and it follows the patient through to different rooms, the Cardiology NPs and Providers are able to verify what actually happened to the patient in the ER,” shared one Cardiology Nurse Practitioner to our team recently. This continuous, cross-unit record provides clinicians with absolute clarity, ensuring that critical diagnostic waveforms are preserved for review anywhere, at any time.

This second-by-second data pipeline continuously feeds a vital foundation for pioneering clinical research. Because cardiac conditions unfold dynamically, researchers need more than sporadic vitals to evaluate how new therapies impact fragile populations.

At the Ann & Robert H. Lurie Children’s Hospital of Chicago, researchers leveraged Sickbay’s advanced streaming data platform to study pediatric heart failure. The research team used Sickbay to analyze and characterize the acute cardiovascular and hemodynamic effects of sacubitril/valsartan in pediatric patients. By capturing continuous, high-resolution physiological streams, the study team tracked precise, nuanced responses to medication that traditional episodic charting would inevitably smooth out or miss entirely.

From tracking rhythm changes across hospital departments to quantifying the acute hemodynamic impacts of a new heart failure regimen, Sickbay transforms raw patient data into a continuous, searchable, and highly actionable asset.

Cardiac Care Deserves Continuous Data

Data capture for cardiac care and cardiac research should follow the continuous evolution of cardiac disease in the patient. When clinicians and researchers can see more of what happens over time, they can better understand risk, treatment response, deterioration, and recovery.

For health systems, that visibility has implications across all patient encounters. It can support stronger clinical confidence, more precise research, better use of physiologic data, and more scalable approaches to cardiac care.

To learn how Sickbay supports continuous data capture for patient monitoring, research, and clinical precision, contact Sickbay to schedule a demo.